Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

(2013) Evangelos Terpos et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

(2012) G. J. Morgan et al.   BLOOD

Guidelines for supportive care in multiple myeloma 2011

(2011) John A. Snowden et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Medical Research Council Myeloma IX Trial: New Clinical Insights on the Anticancer Effects of Zoledronic Acid in Patients With Multiple Myeloma

(2011) James R. Berenson   Clinical Lymphoma Myeloma & Leukemia

Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease

(2011) Evangelos Terpos et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

(2009) E. Terpos et al.   ANNALS OF ONCOLOGY

Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología

(2009) Ramón García-Sanz et al.   MEDICINA CLINICA

Bisphosphonates in Oncology: Rising Stars or Fallen Heroes

(2009) T. Van den Wyngaert et al.   ONCOLOGIST

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER